Mkts

VYNE Therapeutics Inc.

NASDAQ: VYNE
$28.68+0.38 (+1.34%)
As of Sep 21, 8:00 PM ET

Key statistics

Day range
27.7629.00
52-week range
16.0446.95
Today
Open28.81
Previous close28.68
Volume88.4K
Valuation
Market cap93.50M
P/E ratio—
EPS (TTM)—
Income & risk
Dividend / yield—
Beta-0.76
Avg volume47.0K
Discussion

VYNE News

Stories mentioning VYNE from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30Q1 '24Mar 31
Income Statement
Revenue86.00178.0069.00202.0084.00121.00198.0098.00
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development817.00(2,016)4,8816,1249,68410,2487,3063,708
Sales General & Admin
Total Operating Expenses
Operating Income (Loss)(3,816)81.00(7,542)(9,197)(12,770)(13,091)(10,396)(7,380)
Interest Income
Interest Expense
Other Expense231.00(306.00)1,795594.00760.00934.001,0011,139
Pretax Income(3,585)(225.00)(5,747)(8,603)(12,010)(12,157)(9,395)(6,241)
Tax Provision0.004.000.000.004.000.000.000.00
Net Income (Loss)(3,585)40.00(5,755)(8,611)(12,022)(12,157)(9,406)(6,249)
Earnings Per Share (Basic)(0.08)0.00(0.13)(0.20)(0.28)(0.29)(0.22)(0.15)
Earnings Per Share (Diluted)(0.08)0.00(0.13)(0.20)(0.28)(0.29)(0.22)(0.15)
Weighted Average Shares Outstanding (Basic)42,76842,76842,75942,67342,58942,58742,58642,581
Weighted Average Shares Outstanding (Diluted)42,76842,76842,75942,67342,58942,58742,58642,581

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About VYNE

VYNE Therapeutics Inc. (NASDAQ: VYNE) is a stock listed on the Nasdaq Stock Market under the ticker symbol VYNE. It last traded at $28.68 (Sep 21, 2026, 8:00 PM ET), up 1.3% on the day. That gives VYNE Therapeutics a market capitalisation of $93.5M.

Over the past 52 weeks VYNE has traded between $16.04 and $46.95.

Revenue for the quarter ended Mar 31, 2026 was $86.0K; a net loss of $3.6M. Revenue was down 57.4% from $202.0K in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$86.0K-$3.6M-4168.6%
Dec 31, 2025$178.0K$40.0K22.5%
Jun 30, 2025$69.0K-$5.8M-8340.6%
Mar 31, 2025$202.0K-$8.6M-4262.9%

From VYNE Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…